An FDA panel will consider Novavax’s COVID two-dose, protein-based vaccine this week, looking at some reports of adverse reactions, including rare events of myocarditis and pericarditis.
WebMD Health News
…read more
An FDA panel will consider Novavax’s COVID two-dose, protein-based vaccine this week, looking at some reports of adverse reactions, including rare events of myocarditis and pericarditis.
WebMD Health News
…read more